0000899243-22-032731.txt : 20221004 0000899243-22-032731.hdr.sgml : 20221004 20221004173019 ACCESSION NUMBER: 0000899243-22-032731 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221003 FILED AS OF DATE: 20221004 DATE AS OF CHANGE: 20221004 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Maduck Sean CENTRAL INDEX KEY: 0001698310 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 221293263 MAIL ADDRESS: STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED STREET 2: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-10-03 0 0001088856 CORCEPT THERAPEUTICS INC CORT 0001698310 Maduck Sean C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 0 1 0 0 See Remarks Common Stock 2022-10-03 4 M 0 25000 3.29 A 81462 D Common Stock 2022-10-03 4 S 0 25000 25.64 D 56462 D Common Stock 10000 I See Footnote Common Stock 10000 I See Footnote Stock option (right to buy) 3.29 2022-10-03 4 M 0 25000 0.00 D 2025-02-18 Common Stock 25000 57602 D The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.64 to $25.66. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Represents the shares held by Duckhill Capital, LLC of which the reporting person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Represents the shares held by Sean and Molly Maduck Living Trust of which the reporting person is a co-trustee. Fully exercisable. President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission. /s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck 2022-10-04